Journey Medical Corporation (DERM)

Journey Medical Corporation to Participate in A.G.P.’s Annual Virtual Healthcare Conference

SCOTTSDALE, Ariz., May 19, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey...

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form 8-K - Current report

Journey Medical Corporation Reports First Quarter 2026 Financial Results and Recent Corporate Highlights

Total revenues for the first quarter ended March 31, 2026 increased 21% year-over-year to $16.0 million ...

Journey Medical Corporation to Announce First Quarter 2026 Financial Results on May 13, 2026

SCOTTSDALE, Ariz., May 06, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the...

Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material

Form DEF 14A - Other definitive proxy statements

Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors

Form 4 - Statement of changes in beneficial ownership of securities

Form 4 - Statement of changes in beneficial ownership of securities

Form 8-K - Current report

Journey Medical Corporation Secures Contract with Third Major GPO for Emrosi™

SCOTTSDALE, Ariz., April 21, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey...

Form 8-K - Current report

Journey Medical Corporation Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

Total revenues were $61.9 million in FY2025 compared to $56.1 million in FY2024 Emrosi™ generated net revenues...

Journey Medical Corporation to Announce Year End 2025 Financial Results on March 25, 2026

SCOTTSDALE, Ariz., March 18, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical” or the...